Toxicity risk of non-target organs at risk receiving low-dose radiation: case report by Shueng, Pei-Wei et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Radiation Oncology
Open Access Case report
Toxicity risk of non-target organs at risk receiving low-dose 
radiation: case report
Pei-Wei Shueng1,8,9, Shih-Chiang Lin2, Hou-Tai Chang3, Ngot-Swan Chong1, 
Yu-Jen Chen4,5, Li-Ying Wang6, Yen-Ping Hsieh7 and Chen-Hsi Hsieh*1,4
Address: 1Department of Radiation Oncology, Far Eastern Memorial Hospital, Taipei, Taiwan, 2Department of hematology, Far Eastern Memorial 
Hospital, Taipei, Taiwan, 3Department of Chest Medicine, Division of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan, 4Institute 
of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, 5Department of Radiation Oncology, Mackay 
Memorial Hospital, Taipei, Taiwan, 6School and Graduate Institute of Physical Therapy, College of Medicine, National Taiwan University, Taipei, 
Taiwan, 7Department of Healthcare Administration, Asia University, Taichung, Taiwan, 8Department of Radiation Oncology, National Defense 
Medical Center, Taiwan and 9General Education Center, Oriental Technology Institute, Taiwan
Email: Pei-Wei Shueng - shueng@hotmail.com; Shih-Chiang Lin - pigchiang@yahoo.com.tw; Hou-Tai Chang - houtai38@gmail.com; Ngot-
Swan Chong - nschong@mail.femh.org.tw; Yu-Jen Chen - chenmdphd@yahoo.com; Li-Ying Wang - liying@ntu.edu.tw; Yen-
Ping Hsieh - fannyhsieh@hotmail.com; Chen-Hsi Hsieh* - chenci28@ms49.hinet.net
* Corresponding author    
Abstract
The spine is the most common site for bone metastases. Radiation therapy is a common treatment
for palliation of pain and for prevention or treatment of spinal cord compression. Helical
tomotherapy (HT), a new image-guided intensity modulated radiotherapy (IMRT), delivers highly
conformal dose distributions and provides an impressive ability to spare adjacent organs at risk,
thus increasing the local control of spinal column metastases and decreasing the potential risk of
critical organs under treatment. However, there are a lot of non-target organs at risk (OARs)
occupied by low dose with underestimate in this modern rotational IMRT treatment. Herein, we
report a case of a pathologic compression fracture of the T9 vertebra in a 55-year-old patient with
cholangiocarcinoma. The patient underwent HT at a dose of 30 Gy/10 fractions delivered to T8-
T10 for symptom relief. Two weeks after the radiotherapy had been completed, the first course of
chemotherapy comprising gemcitabine, fluorouracil, and leucovorin was administered. After two
weeks of chemotherapy, however, the patient developed progressive dyspnea. A computed
tomography scan of the chest revealed an interstitial pattern with traction bronchiectasis, diffuse
ground-glass opacities, and cystic change with fibrosis. Acute radiation pneumonitis was diagnosed.
Oncologists should be alert to the potential risk of radiation toxicities caused by low dose off-
targets and abscopal effects even with highly conformal radiotherapy.
Background
Intensity-modulated radiotherapy (IMRT) is a powerful
tool which enabled us to achieve desired dose to tumor
and reducing radiation doses to critical structures simulta-
neously. The encouraging and safety results of patients
with various sites of malignancies in the thoracic region
treated by IMRT have been reported recently [1]. In addi-
tion, Gong et al. reported conventionally-fractionated
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image-guided intensity modulated radiotherapy (IG-
IMRT) is a safe and effective treatment for cancer spinal
metastasis [2].
Helical tomotherapy (HT) is a new CT-based rotational
intensity modulated radiotherapy that can deliver highly
conformal dose distributions with an ability to spare crit-
ical organs from radiation exposure [3]. HT is also effec-
tive and feasible for patients with multiple metastatic
diseases [4].
Radiation recall phenomenon is characterized by an
inflammatory reaction within the previously treated radi-
ation field during chemotherapy treatment [5]. In
humans, longer-range effects of radiotherapy occurring
within or between tissues are referred to as abscopal, out-
of-field, or distant bystander responses [6].
A combination of gemcitabine, 5-fluorouracil (5-FU), and
leucovorin (LV) is effective in patients with unresectable
or metastatic biliary tract or gallbladder adenocarcinoma
[7]. Gemcitabine chemotherapy, however, can cause radi-
ation recall followed by standard radiation therapy [8].
Herein, we present a case of radiation recall pneumonitis
with simultaneous abscopal effects following highly con-
formal HT and gencitabine-based chemotherapy for met-
astatic spine lesion in a patient with metastatic
cholangiocarcinoma.
Case presentation
In August, 2008, a 55-year-old man presented to the neu-
rosurgical outpatient department of with a 2-month his-
tory of progressive claudication. The lumbar (L) -spine X-
ray revealed an osteolytic lesion in the convex posterior
border of the L3 vertebra. Magnetic resonance imaging
(MRI) of the spine demonstrated a pathologic compres-
sion fracture with spinal canal stenosis of the thoracic (T)
9 and L3 vertebrae. Abdominal ultrasound and abdomi-
nal computed tomography (CT) scan both revealed a
tumor in the left lobe of the liver. A complete blood
workup showed an elevated carcinoembryonic antigen
(CEA) level (33.9 ng/dl). An echo-guided biopsy of the
liver tumor was performed. Histopathologic examination
of the biopsy specimen showed adenocarcinoma with
positive CK7 and CEA, findings compatible with primary
cholangiocarcinoma. The patient underwent a left lateral
sectionectomy. The pathologic diagnosis was moderately
differentiated cholangiocarcinoma. Two weeks after the
operation, HT with 30 Gy/10 fractions was delivered to
T8-T10 for symptom relief [9]. The vertebral bodies of T8-
T10 were delineated as the clinical target volume (CTV).
The planning target volume (PTV) was defined as the CTV
plus a 3-mm margin for tumor motion and setup uncer-
tainty. The contoured organs at risk (OARs), dose con-
straints/penalty functions and planning parameters are
listed in Tables 1. The field width, pitch, and modulation
factor (MF) used were 2.5 cm, 0.32, and 3.0, respectively.
Two weeks after the radiotherapy had been completed,
the first course of gemcitabine, fluorouracil, and leucov-
orin was delivered. After two weeks of chemotherapy,
however, the patient developed progressive dyspnea.
Chest X-ray showed diffuse reticular interstitial processes
in both lungs. Atypical infection was suspected. The
patient was transferred to the Medical Intensive Care Unit
with intubation. The blood cultures, sputum cultures, and
fungus cultures were all negative. Bronchoscopy to inves-
tigate the pneumonitis was not performed at the request
Table 1: The contoured organs at risk (OARs), dose constraints/penalty functions and planning parameters of plan was listed as below
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Right lung 10 30.00 5 2 10.00 20
Left lung 10 30.00 5 1 15.00 20
Spinal cord 40 20.00 40 45 5.00 40
Heart 10 26.00 10 20 5.00 15
Spleen 5 7.00 5 10 2.00 5
Stomach 11 3 . 0 0 5 1 02 . 0 0 5
Ring* 1 30.00 50 3 28.00 20
Abbriviations:
PTV = Planning target volume; Max = maximal; Min = minimal; DVH = dose-volume histogram; Vol = volume.
*The ring was a dummy structure surrounded PTV with an outer margin 2.5 cm, and a gap of 2 mm from PTV.Radiation Oncology 2009, 4:71 http://www.ro-journal.com/content/4/1/71
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of the patient's family. Follow-up chest CT revealed a dif-
fuse irregular interlobular thickness and honeycombing
of both lungs (Figure 1) indicative of chronic fibrotic
change. The fibrotic change in both lungs in transverse
view was compatible with low dose irradiation of non-tar-
get OARs (Figure 2 and 3). Acute radiation pneumonitis
was diagnosed. The following empirical antibiotics were
administered: Pisutam (2.25 mg) (China Chemical &
Pharmaceutical CO., LTD., Taiwan) 2 vial i.v.d. q8 h;
Cravit® (500 mg) (Sanofi-Aventis Deutschland GmbH,
Germany) 750 mg i.v.d. qd; and Sevatrim® (480 mg)
(Swiss Pharmaceutical CO., LTD., Taiwan) 3 vial i.v.d.
q12 h. Steroid therapy comprising methylprednisolone
(40 mg), 20 mg iv. q8 h was administered for inflamma-
tory lung disease. The patient also received antioxidants
and supportive treatment simultaneously. After one
month in the intensive care unit, the patient stabilized
and was transferred to the hematology ward for further
care.
Discussion
Radiation therapy (RT) is a common and safe treatment to
relieve pain of symptomatic osseous metastases. In addi-
tion, RT is reserved for palliation of prevention or treat-
ment of spinal cord compression. Generally, RT focuses
on limited area for symptom relief. However, RT also is
safe and effective for multiple symptomatic osseous met-
astatic patients as multi-fractionated wide-field radiation
therapy (MF-WFRT) [10].
Radiation pneumonitis in patients undergoing treatment
for lung cancer has been shown to be associated with a
V20 > 20%, where V20 represents the percentage of lung
volume receiving at least 20 Gy [11], and a mean lung
dose > 13.6 Gy [12]. The V20 and mean lung dose in our
patient were 1% and 2.7 Gy, respectively. Therefore, our
plan was a safe protocol for palliative treatment of meta-
static bone disease. Although the low dose around the
irradiation target is usually overlooked, such as the V5 in
the plan presented here (Figure 3) which was only 20%, it
can potentially induce severe radiation toxicity (Figure 2).
Chest computed tomography (CT) post intubation in the  MICU shows interstitial pattern with traction bronchiectasis,  opacities and a diffuse ground-glass pattern, bleb formation in  marginal areas, airspace consolidation and fibrosis in the  bilateral lung fields Figure 1
Chest computed tomography (CT) post intubation in 
the MICU shows interstitial pattern with traction 
bronchiectasis, opacities and a diffuse ground-glass 
pattern, bleb formation in marginal areas, airspace 
consolidation and fibrosis in the bilateral lung fields. 
The coronal views of chest CT.
Chest computed tomography (CT) post intubation in the  MICU shows interstitial pattern with traction bronchiectasis,  opacities and a diffuse ground-glass pattern, bleb formation in  marginal areas, airspace consolidation and fibrosis in the  bilateral lung fields Figure 2
Chest computed tomography (CT) post intubation in 
the MICU shows interstitial pattern with traction 
bronchiectasis, opacities and a diffuse ground-glass 
pattern, bleb formation in marginal areas, airspace 
consolidation and fibrosis in the bilateral lung fields. 
The transverse views of chest CT.
The dose distribution of radiotherapy designed for tomo- therapy Figure 3
The dose distribution of radiotherapy designed for 
tomotherapy. The transverse view of low dose distribution 
is compatible with the recall radiation pneumonitis area.Radiation Oncology 2009, 4:71 http://www.ro-journal.com/content/4/1/71
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Although rare, gemcitabine can induce radiation recall
reactions [13]. The time from gemcitabine administration
to the manifestation of recall reaction ranges from 3 days
to 8 months [8]. Our patient suffered from severe pulmo-
nary toxicity 2 weeks after gemcitabine administration.
Radiographic findings characteristic of radiation-induced
pulmonary changes include ground-glass opacities with
irregular linear opacity and interstitial thickening [14]. In
our patient, the opacities with ground-glass pattern and
bleb formation in the transverse views of chest CT (Figure
2) confined in the previous low dose non-target OAR field
(Figure 3) indicate radiation pneumonitis recalled by
gemcitabine. The diffuse irregular interlobular thickness
and honeycombing of both lungs in the chest CT (Figure
1) are compatible with radiation-induced pulmonary
changes, although no radiaiton was directed to these
fields (Figure 4).
Khan et al.,[15] reported that when rat lung was partially
irradiated, micronucleus formation was observed in non-
irradiated areas of the lung, indicating DNA damage at
these non-irradiated sites. In humans, abscopal events
such as bilateral pneumonitis have been observed in
humans after unilateral irradiation [16]. Additionally, a
survival benefit of local control by simultaneous thoracic
radiochemotherapy in the case of improved distant con-
trol due to chemotherapy and prophylactic cranial irradi-
ation has been reported [17]. These long-range bystander
responses have also been studied in a lung reconstruction
model in which levels of the phosphorylated histone var-
iant γH2AX, a marker of double-strand break (DSBs), were
found to be increased, reaching a maximum by 12 to 48 h
after irradiation, followed by a gradual decrease over the
7-day time course [18]. Biomolecules known to be
involved in bystander responses include interleukin 6 (Il-
6), Il-8, transforming growth factor-β1 (TGF-β1), and
tumor necrosis factor-α (TNFα), reactive oxygen species
(ROS), and reactive nitrogen species [19]. Recently, the
correlation between TGF-β1 and developing radiation
pneumonitis has been reported [20] and the observation
could also partially response to the contribution of bio-
molecules on bystander responses. When distant
bystander responses to radiotherapy occur during cancer
treatment that the potential lung injury could be hap-
pened. If subsequent treatment is radiation recall agents
that it could induce nearly fatal interstitial lung disease as
the case we present here.
The low dose irradiation to non-target OARs noted in this
patient is not unique to tomotherapy, rather it can occur
with any technique that creates a relatively large low dose
volume such as multifield IMRT, volumetric arc therapies
or stereotactic radiation therapy (SRT). For example, inho-
mogeneity corrections have a large influence on the dose
delivered to the PTV and OARs for SRT of lung tumors
[21]. SRT allows for the minimization of normal tissue
volume exposed to high radiation dose that is to mini-
mize toxicity while maximizing tumor control [22]. How-
ever, even in SRT, the large amount of low dose irradiation
to non-target OARs, the incidence of lung toxicity can
become high has been reported by Yamashita et al. [23]
Oncologists should be alert to the potential risk of low
dose irradiation of non-target OARs when reviewing plans
in the lung. It is important to review the low dose volumes
and include the low dose volumes in the dose distribu-
tion, especially if there is a plan to give chemotherapy.
Also, in cases in which there is a chance of recall within
the thorax, a static field Posterior-Anterior (PA) or AP/PA,
or a three-dimensional conformal radiation therapy
(3DCRT) approach with fewer beams and smaller irradi-
ated volume may be preferred for palliative (or radical
treatment) to avoid this problem. In addition, even with
volumetric or helical arc therapy, strong penalty functions
on the lung could reduce the volume of the lung receiving
even low doses.
Conclusion
Non-target OARs can be impacted by arc therapy because
of the low dose bath phenomenon. These effects can be
magnified by agents known or unknown to be associated
with recall effects. Optimization of planning should be
considered in these situations.
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The dose distribution of radiotherapy designed for tomo- therapy Figure 4
The dose distribution of radiotherapy designed for 
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